Illumina has a total of 9281 patents globally, out of which 3896 have been granted. Of these 9281 patents, more than 78% patents are active. United States of America is where Illumina has filed the maximum number of patents, followed by Europe and Australia. Parallelly, USA seems to be the main focused R&D center and is also the origin country of Illumina.
Illumina was founded in 1998 by Larry Bock and Anthony Czarnik. Illumina develops, manufactures and markets integrated systems for the large-scale analysis of genetic variation and biological function. The Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies. As of March 2022, Illumina has a market cap of $51.84 Billion.
Do read about some of the most popular patents of Illumina which have been covered by us in this article and also you can find Illumina patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Illumina patent portfolio.
How many patents does the CEO of Illumina have?
The CEO, Francis deSouza have 0 patents.
How many patents does Illumina have?
Illumina has a total of 9281 patents globally. These patents belong to 1532 unique patent families. Out of 9281 patents, 7293 patents are active.
How many Illumina patents are Alive/Dead?
How Many Patents did Illumina File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
|Year of Patents Filing or Grant||Illumina Applications Filed||Illumina Patents Granted|
How Many Patents did Illumina File in Different Countries?
Countries in which Illumina Filed Patents
|United States Of America||1748|
|Hong Kong (S.A.R.)||485|
|Eurasian Patent Organization||1|
|United Arab Emirates||1|
Where are Research Centers of Illumina Patents Located?
10 Best Illumina Patents
US7057026B2 is the most popular patent in the Illumina portfolio. It has received 1457 citations so far from companies like Omniome Inc, 10X Genomics Inc and Raindance Technologies Inc.
Below is the list of 10 most cited patents of Illumina:
|Publication Number||Citation Count|
Patents acquired by Illumina
Illumina has acquired 9 patents from other companies which is not associated with Illumina.
Below the table shown the patent acquisition of Illumina –
|Quantum Biosystems Inc||1|
|Mosaic Technologies Inc||1|
|Conexio 4 Pty Ltd | Atria Genetics Inc||1|
|Taiwan Semiconductor Manufacturing Company||1|
|Powerchip Technology Corporation||1|
Which Companies are using Illumina Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Illumina patent portfolio are Bank Of America, Mastercard and Chase Bank.
List of the top forward citing Companies –
|Company||Number of Patents|
|Advanced Liquid Logic Inc||37|
|Ariosa Diagnostics Inc||20|
|Qiagen Sciences Llc||11|
Count of 102 and 103 Type Rejections based on Illumina Patents
Top Illumina Patents used in Rejecting Most Patent Applications
|Patent Number||Count of Rejected Applications|
What Percentage of Illumina US Patent Applications were Granted?
Illumina (Excluding its subsidiaries) has filed 1283 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 768 have been granted leading to a grant rate of 78.29%.
Below are the key stats of Illumina patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Illumina?
|Law Firm||Total Applications||Success Rate|
|Knobbe Martens Olson & Bear Llp||205||79.27%|
|Brown Rudnick Llp||58||34.48%|
|The Small Patent Law Group Llc||47||80.85%|
|C O Fletcher Yoder Pc||44||96.55%|
|Weaver Austin Villeneuve & Sampson Llp||39||95.45%|
|Dierker & Kavanaugh P c||38||0.00%|
|C O Haynes Beffel & Wolfeld Llp||27||100.00%|
“We are proud to continue our tradition of driving down the cost of sequencing without compromising accuracy,” said Omead Ostadan, Senior Vice President, Marketing and Products at Illumina. “NextSeq 1000 and 2000 are designed to enable core labs, small to medium research labs and clinical facilities to access high intensity sequencing applications using our industry-leading SBS technology.”
Illumina’s NovaSeqDx platform will address growing demand for a Dx platform to support deeper sequencing at higher throughput. The company also announced the development of a regulatory-cleared version of its high-throughput NovaSequ system, with commercial availability targeted for 2022.
“At Illumina, we are focused on three key areas to scale the reach and impact of genomics—enabling breakthrough genomics research, accelerating the clinical adoption of genomics and delivering fundamentally enabling technology innovations,” said Francis deSouza, Chief Executive Officer at Illumina. “The NextSeq 1000 and 2000 Sequencing Systems, TruSight Software and our partnership with Roche, will accelerate the adoption of research and clinical sequencing for the benefit of humanity.”
EXCLUSIVE INSIGHTS COMING SOON!
What are Illumina’s key innovation segments?
What Technologies are Covered by Illumina?
The chart below distributes patents filed by Illumina in different countries on the basis of the technology protected in patents. It also represents the markets where Illumina thinks it’s important to protect particular technology inventions.
R&D Focus: How Illumina search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Illumina?